Standard methods may not account for the unique instability of siRNA molecules or the complex matrix effects introduced by LNP delivery systems. Reproducible clinical-grade assay development for siRNA requires modality-specific protocols for sample handling, extraction, and quantification to ensure the integrity of the analyte and prevent degradation, which is a common source of variability.

Regulatory bodies like the FDA and MHRA require a clear, consistent data narrative demonstrating the relationship between dose, exposure, and response. Irreproducible bioanalytical data obscures this relationship, making it difficult to establish a safety profile or justify a starting dose in humans. By minimizing clinical risk with highly reproducible assays, sponsors can accelerate their programs toward an 18-24 month IND timeline.

Developing assays intended for regulatory submission requires a robust quality management system and operation within GxP-compliant environments. This includes dedicated laboratory space, validated instrumentation, controlled access, and comprehensive SOPs for every procedure from sample receipt to final reporting. Franklin Biolabs’ >100,000 sq ft facility “ is designed to support these rigorous requirements.

The development of next-generation therapies utilizing siRNA requires a departure from legacy bioanalytical templates. The inherent instability of RNA payloads and the sophisticated chemistry of their LNP delivery vehicles introduce variables that must be rigorously controlled to achieve reproducible results.

A foundational element of a successful program is a phase-appropriate validation strategy. Assays used for early-stage discovery can be qualified as fit-for-purpose, focusing on speed and directional accuracy. As a program advances toward IND-enabling studies, these assays must evolve, undergoing stringent validation under GxP conditions to meet global regulatory expectations (ICH, FDA, MHRA). This tiered approach prevents wasted resources while building a robust data package over time.